Clementia Pharmaceuticals Inc (CMTA) Expected to Post Earnings of -$0.41 Per Share
Wall Street analysts expect Clementia Pharmaceuticals Inc (NASDAQ:CMTA) to report ($0.41) earnings per share for the current fiscal quarter, according to Zacks Investment Research. Zero analysts have provided estimates for Clementia Pharmaceuticals’ earnings. The highest EPS estimate is ($0.32) and the lowest is ($0.46). Clementia Pharmaceuticals posted earnings per share of ($9.54) in the same quarter last year, which indicates a positive year-over-year growth rate of 95.7%. The business is expected to report its next quarterly earnings report on Thursday, August 9th.
On average, analysts expect that Clementia Pharmaceuticals will report full year earnings of ($1.77) per share for the current financial year, with EPS estimates ranging from ($2.00) to ($1.35). For the next financial year, analysts forecast that the business will report earnings of ($1.79) per share, with EPS estimates ranging from ($2.05) to ($1.27). Zacks Investment Research’s earnings per share calculations are an average based on a survey of sell-side analysts that cover Clementia Pharmaceuticals.
Clementia Pharmaceuticals (NASDAQ:CMTA) last posted its quarterly earnings data on Wednesday, May 9th. The company reported ($0.42) earnings per share for the quarter, missing the consensus estimate of ($0.33) by ($0.09).
Several institutional investors have recently added to or reduced their stakes in CMTA. A.R.T. Advisors LLC acquired a new stake in shares of Clementia Pharmaceuticals in the first quarter worth $232,000. J. Goldman & Co LP acquired a new stake in shares of Clementia Pharmaceuticals in the fourth quarter worth $488,000. Birchview Capital LP increased its position in shares of Clementia Pharmaceuticals by 72.7% in the first quarter. Birchview Capital LP now owns 38,000 shares of the company’s stock worth $576,000 after acquiring an additional 16,000 shares in the last quarter. Alps Advisors Inc. increased its position in shares of Clementia Pharmaceuticals by 21.0% in the first quarter. Alps Advisors Inc. now owns 40,943 shares of the company’s stock worth $620,000 after acquiring an additional 7,116 shares in the last quarter. Finally, Victory Capital Management Inc. increased its position in shares of Clementia Pharmaceuticals by 12.7% in the fourth quarter. Victory Capital Management Inc. now owns 34,710 shares of the company’s stock worth $659,000 after acquiring an additional 3,920 shares in the last quarter. 71.24% of the stock is owned by institutional investors.
Clementia Pharmaceuticals opened at $14.20 on Friday, Marketbeat reports. Clementia Pharmaceuticals has a fifty-two week low of $11.72 and a fifty-two week high of $20.15. The firm has a market cap of $438.03 million and a price-to-earnings ratio of -1.79.
About Clementia Pharmaceuticals
Clementia Pharmaceuticals Inc, a clinical stage biopharmaceutical company, develops treatments for patients suffering from bone disorders and other diseases. Its lead product candidate is palovarotene, an oral small molecule for the treatment of fibrodysplasia ossificans progressive, multiple osteochondromas, dry eye disease, and other diseases is in the Phase 3 MOVE Trial.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Clementia Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clementia Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.